Xolair (omalizumab) - Roche, Novartis
Tezspire (tezepelumab-ekko) - AstraZeneca, Amgen
aspirin - Generic mfg.
Dupixent (dupilumab) - Sanofi, Regeneron
Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease. (PubMed, Clin Transl Allergy) - Oct 4, 2026 - "Current evidence suggests biologic therapies provide meaningful benefit in AERD, although available evidence is limited by small sample sizes and heterogeneous designs. Prospective comparative studies are needed to inform optimal biologic selection and sequencing." 
Journal • Review • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Eosinophilia • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis • IL5
http://www.ncbi.nlm.nih.gov/pubmed/42828727
 
Alison J Patev; Anastasia Hagopian; Jennifer K Priessnitz; Joseph K Han; Kent K Lam
 
Oct 4, 2026
 
Prev Next